In general, the rarity of point mutations to KEAP1/NRF2 pathway deregulation were confirmed in SCLC cells, whereas the high frequency of missense mutations in the subset of NSCLC cells represent a molecular and distinctive hallmark [11,21]. This evidence concerns the gene KEAP1 and small cell lung carcinoma.